Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

SYS6090 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our China register that name SYS6090 as an intervention. Synced 9 Nov 2026
2Current trials
0Recruiting now
1Lead sponsor
1Country register
At a glance

SYS6090 is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. All registered phases are Phase 1/2. The lead sponsor is CSPC Megalith Biopharmaceutical Co.,Ltd. The most-studied condition is Unresectable Advanced or Metastatic Colorectal Cancer.

Patient leaflets for SYS6090

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Not yet open2100%

Trials by phase

  • Phase 1/22100%
01

Clinical trials of SYS6090

2 trials
StudyPhaseStatusLead sponsorRegisters
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
NCT07750041 · ClinicalTrials.gov ↗ · Unresectable Advanced or Metastatic Colorectal Cancer
Phase 1/2 Not yet open CSPC Megalith Biopharmaceutical Co.,Ltd China
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
NCT07761286 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
Phase 1/2 Not yet open CSPC Megalith Biopharmaceutical Co.,Ltd China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with SYS6090

2 conditions
Unresectable Advanced or Metastatic Colorectal Cancer1HCC - Hepatocellular Carcinoma1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
CSPC Megalith Biopharmaceutical Co.,Ltd2
04

By country register

RegisterTrialsRecruiting
Clinical trials in China20

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about SYS6090 trials

How many clinical trials are testing SYS6090?

2 current trials in our China register name SYS6090 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are SYS6090 trials recruiting patients?

Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors SYS6090 clinical trials?

The lead sponsor is CSPC Megalith Biopharmaceutical Co.,Ltd. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SYS6090 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SYS6090 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SYS6090 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.